Broadcast technology supplier Pebble Beach Systems (LON: PEB) has won a five-year contract in the US worth £1.3m. There is scope for upside with the US streaming client. This boosts recurring revenues. Cavendish had previously upgraded its 2026 pre-tax profit forecast to £2.7m, and this contract helps to underpin the current estimate. The share price gained 12.15 to 18.5p.
Cognitive assessment products company Cambridge Cognition (LON: COG) has secured a non-exclusive partnership with Ivory that will enable the company to enter the market in India. Forecasts have not been changed due to the uncertainty about the rate of progress in India. This follows a pilot agreement in Europe. Cambridge Cognition could reach breakeven this year. The share price increased 10.1% to 43.5p.
Prospex Energy (LON: PXEN) has restarted the El Romeral power plant in Andalucia, following the repairing of a transformer failure, and electricity sales have commenced from a rental transformer. This is earlier than expected. It will run overnight when prices are higher. The replacement transformer will take six months to arrive. Tom Reynolds has started as chief executive. Hannam & Partners retains its risked NAV at 14.1p/share. The share price improved 8.47% to 3.2p.
Block Energy (LON: BLOE) says a report by Oilfield Production Consultants confirms technical viability of the carbon capture and storage (CCS) project in Georgia. A feasibility study to evaluate requirements and scalability will be undertaken. The share price rose 7.69% to 1.05p.
FALLERS
Skin treatments developer SkinBioTherapeutics (LON: SBTX) has slumped further following last week’s resignation of chief executive Stuart Ashman due to the misrepresentation of information. More details have been provided of the board investigation, and this will lead to the reversal of all accrued royalty income for 2024-25. That was £770,000, so it reduces 2024-25 revenues to £4.64m. This could be an isolated incident, but the investigation continues. This year’s figures will be below expectations, when a performance near to breakeven had been estimated. The underlying potential for the business is thought to be unchanged. There is still £2.92m in the bank, down from £4.78m at the end of June 2025. Given the expected underperformance, it appears more cash will be required this year. The share price dived 49.5% to 6.25p. OptiBiotix Health (LON: OPTI) still owns 5.63% of SkinBioTherapeutics and its share price dipped 7.14% to 5.85p.
Mathematical modelling and biostatistics services provider Physiomics (LON: PYC) increased interim total income from £354,000 to £528,000, including grants. The operating loss rose from £249,000 to £327,000. The share price slipped 11.5% to 0.575p.
On Friday, Genedrive (LON: GDR) completed a £4m subscription and placing at 1p/share and an eight-for-55 open offer is planned that could raise up to £1.5m. David Nugent is converting his £500,000 loan into shares at the same price. The share price declined 8.33% to1.1p.
Infrastructure-as-a-Service automated trading products supplier Beeks Financial Cloud (LON: BKS) says interim trading is in line with expectations. Revenues are estimated to be £14.7m, down from £15.8m. Contracts won late in the period will contribute in the second half. That could contribute around £3.5m to second half revenues. Net cash is £3.3m. The share price fell 4.39% to 218p.